Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 518

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1A
Chunk 518
---
 2024 (the “Business
Combination Agreement”). The stockholders also approved to change Bellevue Life Sciences Acquisition Corp.’s name to “OSR,
Inc.” The stockholders also approved to increase the number of shares of preferred stock that can be issued from 1,000,000 shares
to 20,000,000 shares. The stockholders also approved to provide that directors may be removed by the affirmative vote of the holders of
at least 66 2/3% of the voting power instead of for cause and by the affirmative vote of holders of a majority of the voting power. The
stockholders also approved to eliminate the current limitations on the corporate opportunity doctrine. The stockholders also approved
to provide that the quorum required for stockholder meetings is the holders of one-third in voting power of then outstanding shares of
capital stock entitled to vote at the meeting instead of the holders of a majority in voting power of then outstanding shares of capital
stock entitled to vote at the meeting. The stockholders also approved to all other changes including eliminating certain provisions related
to special purpose acquisition companies that will no longer be relevant following the closing of the Business Combination. The stockholders
also approved to elect nine (9) individuals as directors of OSR, Inc. following the closing of the Business Combination until their respective
successors are duly elected and qualified. The stockholders also approved, for purposes of complying with the applicable listing rules
of the Nasdaq Stock Market LLC, the issuance of shares of OSR, Inc. common stock pursuant to the Business Combination Agreement in connection
with the Business Combination. In connection with the votes to approve the Adjournment Proposal, 57,821 shares of common stock
of the Company were tendered for redemption.

Sponsor Advances

On April 11, 2025 and April 14, 2025, the Sponsor transferred $30,478
and $15,241, respectively, to the Company. These amounts are expected to be applied as reductions to the outstanding balance of due to
Affiliate, which totaled $72,000 as of December 31, 2024. Following these transfers, the outstanding balance is expected to be reduced
to $26,281.

F-24

0001840425
false
FY

    0001840425

    2024-01-01
    2024-12-31

    0001840425
    
      osrh:CommonStockParValue000